Randomized Trialhigh evidence
Rapamycin Exerts Its Geroprotective Effects in the Ageing Human Immune System by Enhancing Resilience Against DNA Damage.
Aging cell·February 1, 2026·PMID 41524558
Why it mattersAge-related immune decline is driven by DNA damage and cellular senescence, and mTOR inhibitors like rapamycin are known to extend lifespan in model organisms. This paper provides the first human evidence that low-dose rapamycin directly reduces DNA damage and senescence in immune cells, offering a mechanistic basis for its potential to slow immune ageing and improve healthspan.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled